drugset / Trial / NCT06799741
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
Timeline
- Start
- 2025-01-07
- Primary completion
- 2026-03-11
- Completion
- 2026-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AV-1 | Monoclonal antibody | 100 mg | Intravenous |
| Subject | AV-1 | Monoclonal antibody | 300 mg | Intravenous |
| Subject | AV-1 | Monoclonal antibody | 900 mg | Intravenous |
Indications
No indication recorded.